CompletedNCT00396565
Extended-release paliperidone for schizophrenia
About this title
A Study to Evaluate Effectiveness and Safety of ER OROS Paliperidone in Patients With Schizophrenia
Read the official source — NCT00396565Researchers compared ER OROS paliperidone, placebo and Olanzapine to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Medication studyAges 20+Japan
Understand this study
What did researchers investigate?
Researchers compared ER OROS paliperidone, placebo and Olanzapine to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 20 years. Other eligibility criteria applied.
- Listed locations
- Aizu-Wakamatsu and 55 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateJuly 2006
- Recruitment status
- Completed
- Enrollment listed in the registry
- 394
- Sponsor
- Janssen Pharmaceutical K.K.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- Over 20 Years
- Official registry ID
- NCT00396565
- Official title
Show the full official title
A Placebo-Controlled Double Blind Comparative Study of JNS007ER in Patients With Schizophrenia
Get this study by email
Recruitment & locations
CompletedAizu-Wakamatsu · Fujioka · Fujisawa
53 more locations
- Fukui
- Hadano
- Himeji
- Hiratsuka
- Hiroshima
- Ibaraki
- Ichikawa
- Iida
- Inazawa
- Itoman
- Kaizuka
- Kanzaki
- Kashihara
- Kitakyushu
- Kochi
- Kōshi
- Kumamoto
- Kurayoshi
- Matsudo
- Matsusaka
- Moriguchi
- Morioka
- Nagoya
- Naha
- Nakagami
- Nankoku
- Nishinomiya
- Noda
- Numazu
- Ohta
- Okinawa
- Oyama
- Ōita
- Sakai
- Sapporo
- Takasaki
- Takatsuki
- Tanba
- Tokyo
- Tottori
- Toyama
- Toyoake
- Toyonaka
- Tōgane
- Tsuyama
- Ueda
- Urasoe
- Uruma
- Yanagawa
- Yao
- Yokkaichi
- Yokohama
- Yokosuka
Questions about this study
What did researchers investigate?
Researchers compared ER OROS paliperidone, placebo and Olanzapine to find out how the approaches affected psychotic symptoms in people with schizophrenia.
Who is behind this study?
The study sponsor is Janssen Pharmaceutical K.K., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including ER OROS paliperidone, Placebo and Olanzapine.
Who was this study for?
This study was for people with schizophrenia. Listed age limits: from 20 years. Other eligibility criteria applied.
